These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 38066700)
1. The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease. Lincoff AM; Ryan DH Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):93-94. PubMed ID: 38066700 [No Abstract] [Full Text] [Related]
2. In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo. Koutroumpakis E; Deswal A Ann Intern Med; 2024 Mar; 177(3):JC31. PubMed ID: 38437690 [TBL] [Abstract][Full Text] [Related]
3. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Ryan DH; Lingvay I; Colhoun HM; Deanfield J; Emerson SS; Kahn SE; Kushner RF; Marso S; Plutzky J; Brown-Frandsen K; Gronning MOL; Hovingh GK; Holst AG; Ravn H; Lincoff AM Am Heart J; 2020 Nov; 229():61-69. PubMed ID: 32916609 [TBL] [Abstract][Full Text] [Related]
4. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D; JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Nauck MA; Quast DR Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484 [TBL] [Abstract][Full Text] [Related]
6. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I; Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417 [TBL] [Abstract][Full Text] [Related]
7. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Newsome P; Francque S; Harrison S; Ratziu V; Van Gaal L; Calanna S; Hansen M; Linder M; Sanyal A Aliment Pharmacol Ther; 2019 Jul; 50(2):193-203. PubMed ID: 31246368 [TBL] [Abstract][Full Text] [Related]
8. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT; JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037 [TBL] [Abstract][Full Text] [Related]
10. Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial. Snitker S; Egebjerg C; Frederiksen M; Sparre T Diabetes Obes Metab; 2022 Nov; 24(11):2273-2276. PubMed ID: 35791625 [No Abstract] [Full Text] [Related]
11. Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes. Basolo A; Fierabracci P; Salvetti G; Santini F J Endocrinol Invest; 2024 May; 47(5):1047-1049. PubMed ID: 38157134 [No Abstract] [Full Text] [Related]
12. Obesity in patients without diabetes undergoing coronary artery bypass graft surgery: Time to select patients for semaglutide. Lan NSR; Ali US; Larbalestier R; Dwivedi G; Fegan PG Obes Res Clin Pract; 2024; 18(1):76-78. PubMed ID: 38331597 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes. Garg SK; Kaur G; Haider Z; Rodriquez E; Beatson C; Snell-Bergeon J Diabetes Technol Ther; 2024 Mar; 26(3):184-189. PubMed ID: 38444317 [No Abstract] [Full Text] [Related]
14. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Mu Y; Bao X; Eliaschewitz FG; Hansen MR; Kim BT; Koroleva A; Ma RCW; Yang T; Zu N; Liu M; Lancet Diabetes Endocrinol; 2024 Mar; 12(3):184-195. PubMed ID: 38330988 [TBL] [Abstract][Full Text] [Related]
15. Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis. He K; Guo Q; Zhang H; Xi W; Li J; Jing Z Diabetes Obes Metab; 2022 Apr; 24(4):722-726. PubMed ID: 34866313 [No Abstract] [Full Text] [Related]
16. Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes? Updike WH; Pane O; Franks R; Saber F; Abdeen F; Balazy DD; Carris NW Drugs; 2021 Jun; 81(8):881-893. PubMed ID: 33929717 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Lau DCW; Batterham RL; le Roux CW Expert Rev Clin Pharmacol; 2022 Mar; 15(3):251-267. PubMed ID: 35466848 [TBL] [Abstract][Full Text] [Related]
18. Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese. Slawson DC Am Fam Physician; 2021 Jul; 104(1):96-97. PubMed ID: 34264618 [No Abstract] [Full Text] [Related]
19. A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity. Strathe A; Horn DB; Larsen MS; Rubino D; Sørrig R; Tran MTD; Wharton S; Overgaard RV Diabetes Obes Metab; 2023 Nov; 25(11):3171-3180. PubMed ID: 37424165 [TBL] [Abstract][Full Text] [Related]